Abstract
Abstract Background and Aims Durable clinical remission, endoscopic healing, and biomarker normalization are key treatment goals for Crohn’s disease. The selective anti-interleukin-23 p19 inhibitor risankizumab demonstrated efficacy and safety in moderately to severely active Crohn’s disease. This post hoc analysis of data from the pivotal risankizumab maintenance study assessed whether risankizumab maintenance therapy sustained the clinical and endoscopic outcomes achieved with risankizumab induction therapy. Methods We evaluated 462 patients who achieved a clinical response to risankizumab intravenous induction treatment and were re-randomized to receive subcutaneous risankizumab 360 mg, subcutaneous risankizumab 180 mg, or placebo [withdrawal] every 8 weeks for 52 weeks in the randomized, controlled FORTIFY maintenance study. Maintenance of clinical, endoscopic, and biomarker endpoints at week 52 among patients who achieved these endpoints after 12 weeks of induction treatment was evaluated. Results A significantly higher proportion of patients receiving maintenance treatment with risankizumab 360 mg or 180 mg compared with placebo [withdrawal] maintained Crohn’s Disease Activity Index remission [68.6%, 70.8%, vs 56.3%; p <0.05], stool frequency/abdominal pain remission [69.2%, 64.1%, vs 50.5%; p <0.01], endoscopic response [70.2%, 68.2%, vs 38.4%; p <0.001], endoscopic remission [74.4%, 45.5%, vs 23.9%; p <0.05], and Simple Endoscopic Score for Crohn’s Disease of 0–2 [65.5%, 36.7%, vs 21.9%]. Most patients [56.8%–83.3%] who achieved normalized fecal calprotectin or C-reactive protein during induction sustained them with maintenance risankizumab. Conclusions Subcutaneous risankizumab maintenance therapy results in durable improvement in clinical and endoscopic outcomes over 1 year in patients with moderately to severely active Crohn’s disease.
